BMEA - Biomea Fusion, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Redwood City,
United States
Type: Equity
BMEA price evolution
BMEA
| (in millions $) | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $202.5 | $225.94 | $88.93 | $117.82 |
| Long term investments | ||||
| Property, plant & equipment | $17.39 | $18.48 | $19.47 | $7.99 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $225.09 | $248.67 | $112.64 | $129.31 |
| Current liabilities | ||||
| Accounts payable | $3.19 | $4.15 | $5.33 | $6.83 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $16.21 | $14.36 | $18.77 | $19.1 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $25.48 | $24.37 | $29.51 | $20.77 |
| Shareholders' equity | ||||
| Retained earnings | -$213.94 | -$185.51 | -$160.62 | -$131.57 |
| Other shareholder equity | -$0 | |||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $117.82 | $176.56 | $62.22 | $0.27 |
| Long term investments | ||||
| Property, plant & equipment | $7.99 | $5.69 | $0.29 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $129.31 | $185.71 | $62.53 | $0.27 |
| Current liabilities | ||||
| Accounts payable | $6.83 | $1.33 | $0.73 | $0.27 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.1 | $4.64 | $1.62 | $0.29 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $20.77 | $6.92 | $1.62 | $0.29 |
| Shareholders' equity | ||||
| Retained earnings | -$131.57 | -$49.74 | -$8.18 | -$2.85 |
| Other shareholder equity | -$0 | -$0.01 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $23.48 | $17.47 | $16.4 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.59 | $0.22 | $0.03 | |
| Net income | ||||
| Net income | -$22.89 | -$17.26 | -$16.37 | |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5.33 | $1.2 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$5.32 | -$1.2 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $28.04 | $27.82 | $20.44 | -$33.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.75 | $0.35 | $0.03 | $153.19 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$13.42 | $2.75 | $10.48 | $84.4 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$33.35 | -$0.05 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $153.19 | $65.97 | $1.44 | |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $84.4 | $61.46 | $0.16 | |
News
|
Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why
Zacks via Yahoo Finance
12 Dec 2023
|
|
Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up
Zacks via Yahoo Finance
18 Oct 2023
|
|
Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year?
Zacks via Yahoo Finance
5 Oct 2023
|
|
Biomea Fusion Stock Is Trading Higher Today - Here's Why
Benzinga via Yahoo Finance
26 Jun 2023
|
|
Biomea Fusion stock soars after release of clinical data on diabetes treatment
Market Watch
26 Jun 2023
|
|
10 Best-Performing Stocks To Invest In
GoBankingRates via AOL
13 Jun 2023
|
|
Top Healthcare Stocks for May 2023
Investopedia
11 May 2023
|
|
individual investors who own 31% along with institutions invested in Biomea Fusion, Inc....
Simply Wall St. via Yahoo Finance
23 Apr 2023
|
|
These 5 High-Growth Small-Cap Stocks Surged More Than 100% In Q1: What's Next? By Benzinga
Investing.com
5 Apr 2023
|
|
Tracking Baker Brothers Portfolio: Q4 2022 Update
Seeking Alpha
5 Apr 2023
|
Fundamentals
| Market cap | $398.40M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 35.70M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 12.49 |
| Quick ratio | N/A |